Aurinia Pharmaceuticals (AUPH) Gains from Investment Securities (2020 - 2026)

Aurinia Pharmaceuticals has reported Gains from Investment Securities for 7 years, with the latest figure at -$581000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 106.5% year-over-year to -$581000.0; the trailing twelve-month figure through Mar 2026 stood at -$601000.0 (down 109.8% YoY), and the FY2025 full-year result was $2.8 million, changed N/A from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$581000.0, down from -$276000.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $11.9 million in Q2 2023, with the low at -$5.9 million in Q3 2025.
• Historically, Gains from Investment Securities has averaged $2.4 million across 5 years, with a median of $17000.0 in 2023.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities tumbled 2280.95% — and 2024, when it soared 16370.59%.
• Aurinia Pharmaceuticals' Gains from Investment Securities stood at -$779000.0 in 2022, then jumped by 1170.73% to $8.3 million in 2023, then slumped by 117.49% to -$1.5 million in 2024, then soared by 81.08% to -$276000.0 in 2025, then plunged by 110.51% to -$581000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$581000.0 (Q1 2026), -$276000.0 (Q4 2025), and -$5.9 million (Q3 2025), per Business Quant data.